Hydra Biosciences, Cubist form collaboration

Hydra Biosciences has announced an agreement with Cubist Pharmaceuticals Inc. for a joint collaboration to develop novel ion channel drugs.

Register for free to listen to this article
Listen with Speechify

CAMBRIDGE, Mass. ­– Hydra Biosciences has announced an agreementwith

Cubist Pharmaceuticals Inc. for a joint collaboration todevelop novel ion channel drugs.


The deal focuses on Hydra's research and development programfor ion channel compounds that target the TRPA1 receptor, which is believed tohave an important role in pain management.


Under the terms of the agreement, Hydra receives an upfrontpayment of $5 million from Cubist. The agreement allows for Cubist to supportHydra`s internal development on the TRPA1 program by providing $5M in researchand development funding per year for two years, with an option to renew. Thejoint development program will build on the existing R&D base of Hydra`sTRPA1 compounds, preclinical data, and pharmacology studies. As thecollaboration progresses into potential future stages, Hydra is eligible for potentialdevelopment milestones and royalties on products produced from the jointprogram. The goal of the program is to identify TRPA1 drug candidates for useas acute care therapeutics for the management of pain.


"As we continue to build an acute care pipeline, we areexcited to develop a partnership with Hydra that provides us access to a novelplatform for developing acute care therapeutics for the management ofpain," says Steven Gilman, Ph.D., chief scientific officer of CubistPharmaceuticals.


"Weare pleased to collaborate with Cubist and to advance innovative drug candidatesusing our ion channel platform," says Russell Herndon, Chief ExecutiveOfficer of Hydra Biosciences. "While our platform has potentially broadapplications in the treatment of pain, inflammation, cardiovascular and otherdiseases, this collaboration is a step forward in advancing our pipeline fornovel ion channel drugs for pain management."  

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue